Covid-19 Therapeutic Research Company
Featuring groundbreaking technologies that assess, diagnosis, and treat COVID-19 like never before.
CovInnovations™ is a company created to bring to market three COVID-19-related technologies: a successful treatment, a 2-minute RNA test and a susceptibility test. Company efforts have focused primarily on the treatment, since of the three technologies this has the greatest potential for social and financial benefit in the shortest amount of time.
Our products are designed to alleviate the fear, significantly reduce the deaths, relax the restrictions we face in our community and integrate our world back to pre-pandemic times.
Committed to Defeating COVID-19
As COVID-19 continues to cripple nations across the world physically and economically, Covinnovations™ offers a solution in the form of COVI-001.
This groundbreaking treatment is used to directly combat and halt COVID-19 after people have become infected with the disease, particularly those with intense reactions who have been hospitalized and are receiving oxygen.
Covinnovations™ was created to develop technologies and solutions directly related to the COVID-19 pandemic. Our patent-pending treatments are a true game changer in the battle against COVID-19.
What is COVI-001?
COVI-001 is a combination of two FDA approved medications that is a revolutionary advance for patients with severe symptoms who are admitted to the hospital and need oxygen or are intubated. There is no treatment in the world like COVI-001.
The COVID-19 infection has two stages. The first stage is viral replication for which many drugs have been shown to provide benefit. Most people survive the first stage without serious incident. A small percentage go on to the second stage which is characterized by an overactive immune response referred to as a cytokine storm that often leads to death. There is no therapeutic available which is widely accepted to be effective that treats COVID-19 after the inflammatory phase of the disease takes hold other than dexamethasone, which provides mild benefit. Enter COVI-001.
With COVI-001, Covinnovations™ has identified a drug that appears to terminate the cytokine storm by suppressing IL-6 activity. A retrospective study demonstrated a 68% reduction in mortality (p<0.05) and a 37% reduction in length of hospital stay (p<0.01) in patients hospitalized with COVID-related hypoxia when compared to standard of care. Patients in the group provided the drug had a 93.6% survival rate as compared to the control group which had a survival rate of 78.5%.
Covinnovations™ is proceeding with FDA approval to fast track COVI-001 for Emergency Use Authorization (EUA). Once approved, COVI-001 will become the standard treatment for all hospitalized COVID-19 patients in the U.S. who require oxygen support. As a result, COVI-001 will become the standard of care around the world. This advance in treatment will equate to millions and millions of doses of COVI-001 administered worldwide. Our research indicates that there is no other late-stage treatment like COVI-001. We are receiving funding to complete the FDA Emergency Use Authorization (EUA) fast track process which will then allow for full-scale production and distribution of this revolutionary treatment. Our clinical scientists have established trial protocols that are ready to deploy around the world.
PLEASE FILL THE FORM BELOW OR CALL US AT (833) 702-1888
